Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

Literature DB >> 7644523

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

P G Coulie¹, F Lehmann, B Lethé, J Herman, C Lurquin, M Andrawiss, T Boon.

Abstract

We have identified an antigen recognized on a human melanoma by autologous cytolytic T lymphocytes. It is encoded by a gene that is expressed in many normal tissues. Remarkably, the sequence coding for the antigenic peptide is located across an exon-intron junction. A point mutation is present in the intron that generates an amino acid change that is essential for the recognition of the peptide by the anti-tumor cytotoxic T lymphocytes. This observation suggests that the T-cell-mediated surveillance of the integrity of the genome may extend to some intronic regions.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1995 PMID： 7644523 PMCID： PMC41269 DOI： 10.1073/pnas.92.17.7976

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

33 in total

1. Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells.

Authors: C Lurquin; A Van Pel; B Mariamé; E De Plaen; J P Szikora; C Janssens; M J Reddehase; J Lejeune; T Boon
Journal: Cell Date: 1989-07-28 Impact factor: 41.582

2. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).

Authors: C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham
Journal: Nucleic Acids Res Date: 1989-04-11 Impact factor: 16.971

3. Improved tools for biological sequence comparison.

Authors: W R Pearson; D J Lipman
Journal: Proc Natl Acad Sci U S A Date: 1988-04 Impact factor: 11.205

4. NK susceptibility varies inversely with target cell class I HLA antigen expression.

Authors: W J Storkus; D N Howell; R D Salter; J R Dawson; P Cresswell
Journal: J Immunol Date: 1987-03-15 Impact factor: 5.422

5. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes.

Authors: P Boël; C Wildmann; M L Sensi; R Brasseur; J C Renauld; P Coulie; T Boon; P van der Bruggen
Journal: Immunity Date: 1995-02 Impact factor: 31.745

6. Expression of HLA-A, -B, and -C and beta 2-microglobulin antigens in human choriocarcinoma cell lines.

Authors: J Trowsdale; P Travers; W F Bodmer; R A Patillo
Journal: J Exp Med Date: 1980-08-01 Impact factor: 14.307

7. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure.

Authors: B Seed; A Aruffo
Journal: Proc Natl Acad Sci U S A Date: 1987-05 Impact factor: 11.205

8. Structure of the gene of tum- transplantation antigen P35B: presence of a point mutation in the antigenic allele.

Authors: J P Szikora; A Van Pel; V Brichard; M André; N Van Baren; P Henry; E De Plaen; T Boon
Journal: EMBO J Date: 1990-04 Impact factor: 11.598

9. Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide.

Authors: C Sibille; P Chomez; C Wildmann; A Van Pel; E De Plaen; J L Maryanski; V de Bergeyck; T Boon
Journal: J Exp Med Date: 1990-07-01 Impact factor: 14.307

10. An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3).

Authors: S R Burrows; T B Sculley; I S Misko; C Schmidt; D J Moss
Journal: J Exp Med Date: 1990-01-01 Impact factor: 14.307

121 in total

Review 1. Heat shock proteins: the fountainhead of innate and adaptive immune responses.

Authors: S Basu; P K Srivastava
Journal: Cell Stress Chaperones Date: 2000-11 Impact factor: 3.667

2. Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors: Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal: World J Immunol Date: 2014-03-27

3. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Authors: E Jäger; S Gnjatic; Y Nagata; E Stockert; D Jäger; J Karbach; A Neumann; J Rieckenberg; Y T Chen; G Ritter; E Hoffman; M Arand; L J Old; A Knuth
Journal: Proc Natl Acad Sci U S A Date: 2000-10-24 Impact factor: 11.205

Review 4. Database of T cell-defined human tumor antigens: the 2013 update.

Authors: Nathalie Vigneron; Vincent Stroobant; Benoît J Van den Eynde; Pierre van der Bruggen
Journal: Cancer Immun Date: 2013-07-15

Review 5. VEGF as a mediator of tumor-associated immunodeficiency.

Authors: J E Ohm; D P Carbone
Journal: Immunol Res Date: 2001 Impact factor: 2.829

6. Inducing autoimmune disease to treat cancer.

Authors: D M Pardoll
Journal: Proc Natl Acad Sci U S A Date: 1999-05-11 Impact factor: 11.205

7. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Authors: Beatriz M Carreno; Vincent Magrini; Michelle Becker-Hapak; Saghar Kaabinejadian; Jasreet Hundal; Allegra A Petti; Amy Ly; Wen-Rong Lie; William H Hildebrand; Elaine R Mardis; Gerald P Linette
Journal: Science Date: 2015-04-02 Impact factor: 47.728